[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553129":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":10,"locations":24,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients receive genomic counseling and genomic testing education, undergo blood or saliva collection, provide previously collected tissue sample and have medical records reviewed on study. Patients and healthcare providers receive results of any genetic variants found on testing.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-interventional study",[9],[20],{"name":21,"affiliation":22,"role":23},"Janani S. Reisenauer, M.D.","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[25],{"facility":22,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-92.4699,44.02163,{"lat":36,"lon":35},[39,44],{"name":40,"role":41,"phone":42,"phoneExt":10,"email":43},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100553129","molecular-analysis-of-suspected-or-high-risk-lung-cancer-to-drive-individualized-care-interception-for-suspected-lung-cancer-100553129",false,"NCT06482073","Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)","Inclusion Criteria:\n\n* Subject age 18 years and older\n* Subject is scheduled\u002Fwas scheduled for a bronchoscopy as part of standard of care\n* Subject with a moderate to high risk of lung cancer based on clinical demographic and radiologic information or with suspected metastatic disease\n* Ability to provide blood or saliva sample\n* Ability to provide archived tissue\n* Subject is able to understand and adhere to study requirements and able to provide informed consent\n\nExclusion Criteria:\n\n* Individuals who have situations that would limit compliance with the study requirements\n* Institutionalized (i.e. federal medical prison)\n* Pregnant\n* Prior germline genetic testing with a 40+ multi-gene panel within the last 1 year of enrollment\n* Prior somatic tissue (250+ gene) testing within the prior 3 months of enrollment","ALL","18 Years",{"count":56,"type":57},40,"ESTIMATED","OBSERVATIONAL","This study evaluates the effectiveness of robotic biopsies in providing information about hereditary or cancer specific genetic variants that may have a role in diagnosis of cancer and to develop genetic results and medical record databank for future studies.",[61,62],"Lung Carcinoma","Metastatic Malignant Neoplasm in the Lung","2026-02-24",{"date":65,"type":66},"2026-02-27","ACTUAL",{"date":68,"type":66},"2024-06-24",{"date":70,"type":57},"2027-07-01",{"name":5,"class":6},1]